Replies to post #1093 on Pure Bioscience, Inc. (PURE)

[236T568]

yet another paid research report:

http://www.seethruequity.com/disclosures/

"In some but not in all instances, SeeThruEquity and/or its officers, directors or affiliates may receive compensation from companies featured in its reports for non report-related services which may include charges for presenting at SeeThruEquity investor conferences, distributing press releases and performing certain other ancillary services. Such compensation is received on the basis of a fixed fee and made without regard to the opinions and conclusions in its research reports. The fee to present at SeeThruEquity conferences is no more than seven thousand dollars, and the fee for distributing press releases is no more than fifteen hundred dollars. The fees for performing certain other ancillary services vary depending on the company and service provided but generally do not exceed five thousand dollars. In no event is a company on which SeeThruEquity has issued a report required to engage it with respect to these non report-related services. SeeThruEquity and/or its affiliates may have a long equity position with respect to a non-controlling interest in the publicly traded shares of companies featured in its reports, and follows customary internal trading restrictions pending the release of its reports. In compliance with Section 17(b) of the Securities Act of 1933, any and all compensation received from a specific company is publicly stated in all applicable reports and other correspondence. Please refer to the specific company’s report for additional details on such matters."

PURE price target $2.45


https://finance.yahoo.com/news/seethruequity-initiates-coverage-pure-bioscience-130000817.html